CIK 0000886744 · Large accelerated filer
GERON CORP
Sign in to watch- Ticker
- GERN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 752287752
- Phone
- 6504737700
- Business address
- 919 EAST HILLSDALE BOULEVARD, SUITE 250, FOSTER CITY, CA, 94404
- Former names
- GERON CORPORATION
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-18 | Ziegler James EVP, Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +529,000 | 529,000 | ||
| 2025-02-18 | Ziegler James EVP, Chief Commercial Officer | Grant or award · Restricted Stock Units | +89,000 | 89,000 | ||
| 2025-02-18 | ROBERTSON MICHELLE EVP, Chief Financial Officer | Grant or award · Stock Option (right to buy) | +656,000 | 656,000 | ||
| 2025-02-18 | ROBERTSON MICHELLE EVP, Chief Financial Officer | Grant or award · Restricted Stock Units | +110,000 | 110,000 | ||
| 2024-12-31 | Spiegel Robert J. Director | Grant or award | +2,206 | $3.54 | $8K | 172,391 |
| 2024-12-31 | Spiegel Robert J. Director | Grant or award | −2,206 | 172,391 | ||
| 2024-11-11 | Eid Joseph EVP, Research and Development | Grant or award · Stock Option (right to buy) | −2,500,000 | 2,500,000 | ||
| 2024-09-30 | Spiegel Robert J. Director | Grant or award | +1,767 | $4.54 | $8K | 170,185 |
| 2024-09-30 | Spiegel Robert J. Director | Grant or award | −1,767 | 170,185 | ||
| 2024-09-09 | Ziegler James EVP, Chief Commercial Officer | Grant or award · Stock Option (right to buy) | −1,600,000 | 1,600,000 | ||
| 2024-07-08 | GRETHLEIN ANDREW J EVP, Chief Operating Officer | Option exercise | +674,348 | $1.72 | $1.2M | 674,348 |
| 2024-07-08 | GRETHLEIN ANDREW J EVP, Chief Operating Officer | Sale | −674,348 | $4.56 | $3.1M | 0 |
| 2024-07-08 | GRETHLEIN ANDREW J EVP, Chief Operating Officer | Option exercise · Stock Option (right to buy) | −221,544 | 0 | ||
| 2024-07-08 | GRETHLEIN ANDREW J EVP, Chief Operating Officer | Option exercise · Stock Option (right to buy) | −452,804 | 0 | ||
| 2024-06-28 | Spiegel Robert J. Director | Grant or award | +1,916 | $4.24 | $8K | 168,418 |
| 2024-06-28 | Spiegel Robert J. Director | Grant or award | −1,916 | 168,418 | ||
| 2024-06-10 | Feller Faye EVP, Chief Medical Officer | Option exercise | +112,500 | $1.06 | $119K | 112,500 |
| 2024-06-10 | Feller Faye EVP, Chief Medical Officer | Option exercise | +20,000 | $1.06 | $21K | 20,000 |
| 2024-06-10 | Feller Faye EVP, Chief Medical Officer | Option exercise | +155,400 | $1.30 | $201K | 155,400 |
| 2024-06-10 | Feller Faye EVP, Chief Medical Officer | Sale | −287,900 | $4.63 | $1.3M | 0 |
Page 3 of 7 · 138 trades